The World Health Organization is expressing hope about the experimental antiviral drug remdesivir for treating hospitalized COVID-19 patients, saying it welcomes recent data from randomized control trials done in the US.
"There's signals of hope there for the potential use of the drug and we will be engaging in discussions with Gilead and the U.S. government as to how this drug may be made more widely available as further data emerges on its effectiveness.''
Remdesivir, which is produced by Gilead Sciences, was previously granted emergency use authorization from the U.S. Food and Drug Administration, greatly waiving the usual formal safety standards.
Assuming one patient would need a usage period of ten days, Gilead expects to donate the drug by the end of this month to more than 140-thousand patients, and says it would be able to make one-million rounds by the end of this year, if needed.
Japanese health authorities are planning to approve remdesivir's emergency-use as early as Thursday.
Worldwide efforts are in high gear to find the vaccine as well.
According to CNBC, the pharmaceutical giant Pfizer on Tuesday started tests on humans in the U.S.
Human trials with this potential vaccine BNT162 have already been underway since late last month in Germany.
According to a report from the World Health Organization, more than 100 candidate vaccines are under preclinical evaluation with at least eight already in the human trial stage as of Tuesday.
The WHO chief is urging the world to defeat the virus together.
"This virus will be with us for a long time and we must come together to develop and share the tools to defeat it."
He added the world will prevail providing there is national unity and global solidarity.
KIM Bo-kyoung, Arirang News.